Xilio Development Inc (XLO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Xilio Development Inc stock (XLO) is currently trading at $8.53. Xilio Development Inc PS ratio (Price-to-Sales) is 14.05. Analyst consensus price target for XLO is $20.00. WallStSmart rates XLO as Sell.
- XLO PE ratio analysis and historical PE chart
- XLO PS ratio (Price-to-Sales) history and trend
- XLO intrinsic value — DCF, Graham Number, EPV models
- XLO stock price prediction 2025 2026 2027 2028 2029 2030
- XLO fair value vs current price
- XLO insider transactions and insider buying
- Is XLO undervalued or overvalued?
- Xilio Development Inc financial analysis — revenue, earnings, cash flow
- XLO Piotroski F-Score and Altman Z-Score
- XLO analyst price target and Smart Rating
Xilio Development Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Xilio Development Inc (XLO) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Xilio Development Inc (XLO) Key Strengths (2)
Revenue surging 694.00% year-over-year
Trading at 1.25x book value, attractively priced
Supporting Valuation Data
Xilio Development Inc (XLO) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 14.1x annual revenue
Small-cap company with higher risk but more growth potential
Moderate institutional interest at 39.01%
Supporting Valuation Data
Xilio Development Inc (XLO) Detailed Analysis Report
Overall Assessment
This company scores 31/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 2 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Price/Book. Valuation metrics including Price/Book (1.25) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 694.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (14.05) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -132.50%, Operating Margin at -86.50%, Profit Margin at -80.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -132.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 694.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
XLO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
XLO's Price-to-Sales ratio of 14.05x trades 84% above its historical average of 7.62x (57th percentile), historically expensive. The current valuation is 23% below its historical high of 18.15x set in Mar 2026, and 1091% above its historical low of 1.18x in Mar 2026. Over the past 12 months, the PS ratio has expanded from ~1.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Xilio Development Inc (XLO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Xilio Development Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 44M with 694% growth year-over-year. The company is currently unprofitable, posting a -80.0% profit margin.
Key Findings
Revenue growing at 694% YoY, reaching 44M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 41% of revenue (18M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -80.0% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Xilio Development Inc maintain 694%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Xilio Development Inc.
Bottom Line
Xilio Development Inc is a high-conviction growth story with revenue accelerating at 694% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -80.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Xilio Development Inc(XLO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Xilio Therapeutics, Inc., a biotechnology company, designs immunotherapies to improve the immune systems of cancer patients. The company is headquartered in Waltham, Massachusetts.